The DOI matches its Crossref record.
Prognostic significance of morphologic parameters in renal cell carcinoma
Abstract
The prognostic significance of morphologic parameters was evaluated in 103 patients with renal cell carcinoma diagnosed during 1961--1974. Pathologic material was classified as to pathologic stage, tumor size, cell arrangement, cell type and nuclear grade. Four nuclear grades (1--4) were defined in order of increasing nuclear size, irregularity and nucleolar prominence. Nuclear grade was more effective than each of the other parameters in predicting development of distant metastasis following nephrectomy. Among 45 patients who presented in Stage I, tumors classified as nuclear grade 1 did not metastasize for at least 5 years, whereas 50% of the higher grade tumors did so. Moreover, among Stage I tumors there was a significant difference in subsequent metastatic rate between nuclear grades 1 and 2. There was an apparent positive relationship between cell type and metastatic rate; clear cell tumors were less aggressive than predominantly granular cell tumors (metastatic rate 38% versus 71%). This relationship in part a function of the nuclear grade: only 5% of grade 3 and 4 tumors consisted of clear cells, whereas such high grades were seen in 57% of granular cell tumors. The size of the primary correlated well with the stage at the time of surgery. However, with the exception of extremely large and small tumors, the size was not useful in predicting the subsequent course of patients treated for Stage I tumors. Nuclear grade was the most significant prognostic criterion for the outcome of Stage I renal cell carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hsieh, J. J., Purdue, M. P., Signoretti, S., Swanton, C., Albiges, L., Schmidinger, M., Heng, D. Y., Larkin, J., & Ficarra, V. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.9 · Cited by 2,426
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes
Dalgliesh, G. L., Furge, K., Greenman, C., Chen, L., Bignell, G., Butler, A., Davies, H., Edkins, S., Hardy, C., Latimer, C., et al. (2010) · Nature · doi:10.1038/nature08672 · Cited by 1,173
The clinically inapparent adrenal mass: update in diagnosis and management
Mansmann, G., Lau, J., Balk, E., Rothberg, M., Miyachi, Y., & Bornstein, S. R. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0031 · Cited by 781
(2002) · PubMed · Cited by 550
Biswas, S., Troy, H., Leek, R., Chung, Y.-L., Li, J.-L., Raval, R. R., Turley, H., Gatter, K., Pezzella, F., Griffiths, J. R., et al. (2010) · Journal of Oncology · doi:10.1155/2010/757908 · Cited by 89
Prognostic Significance of Histomorphologic Parameters in Diffuse Malignant Peritoneal Mesothelioma
Cerruto, C. A., Brun, E. A., Chang, D., & Sugarbaker, P. H. (2006) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2006-130-1654-psohpi · Cited by 78
Kiseljak-Vassiliades, K., Bancos, I., Hamrahian, A., Habra, M. A., Vaidya, A., Levine, A. C., & Else, T. (2020) · Endocrine Practice · doi:10.4158/dscr-2020-0567 · Cited by 66
Stabilization of MCRS1 by BAP1 Prevents Chromosome Instability in Renal Cell Carcinoma
Peng, J., Ma, J., Li, W., Mo, R., Zhang, P., Gao, K., Jin, X., Xiao, J., Wang, C., & Fan, J. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.08.013 · Cited by 46
Serum Levels of the IL-6 Family of Cytokines Predict Prognosis in Renal Cell Carcinoma (RCC)
Gudbrandsdottir, G., Aarstad, H. H., Bostad, L., Hjelle, K. M., Aarstad, H. J., Bruserud, Ø., Tvedt, T. H. A., & Beisland, C. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02655-z · Cited by 35
Campbell, L., Nuttall, R., Griffiths, D., & Gumbleton, M. (2009) · Cancer · doi:10.1002/cncr.24389 · Cited by 29
Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope?
Cosso, F., Roviello, G., Nesi, G., Shabani, S., Spatafora, P., Villari, D., & Catalano, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044243 · Cited by 18
Metadata
- Authors
- Fuhrman, S. A., Lasky, L. C., & Limas, C.
- Venue
- The American Journal of Surgical Pathology
- Published
- 1982-10
- Volume
- 6
- Issue
- 7
- Pages
- 655-664
- ISSN
- 0147-5185 (ISSN-L)
- OpenAlex
- W2039545078
- Cited by
- 2,724
- References
- 0
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.